Photo: ViewStock/Getty Images
Axon Therapies, a medtech company focused on heart failure therapies, announced it closed an oversubscribed $32 million Series A funding round, co-led by new investors Earlybird Venture Capital and Santé Ventures.
Existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare also participated in the round.
Axon is developing a therapy that leverages Splanchnic Ablation for Volume Management (SAVM). This procedure redirects blood volume from the heart to the abdominal region, thereby reducing fluid overload and pulmonary capillary wedge pressure. The therapy aims to treat the root cause of heart failure.
The funding will support the company's clinical trials for its splanchnic ablation therapy in patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and a second multi-center study of splanchnic ablation in Heart Failure with Reduced Ejection Fraction (HFrEF).
In addition to the funding, the company announced that its cofounder and former chief scientific officer, Zoar Engelman, has been appointed CEO.
"Our implant-free, minimally invasive therapy is designed to address a core physiological driver of the disease. This funding positions us to advance to pivotal trials and bring hope to patients who urgently need new solutions," Engelman said.
Caregility, an enterprise telehealth company, has raised an additional $25.1 million in Series A-2 Preferred Stock and Series C funding rounds, bringing its total raise to $92 million.
Star Mountain Capital led the round, with participation from management, York Wang, initial founders and high-net-worth healthcare-focused investors.
The company will use the funds to scale its initiatives, including its AI tools, computer vision, sensor-based tools and ambient listening technology.
"Caregility is setting the standard for innovation in hospital-based virtual care, with groundbreaking capabilities such as edge-based Computer Vision AI and audio sensing room duress detection," said Dr. David Shulkin, M.D., independent board member of Caregility.
"Caregility has expanded these advancements globally, and their platform is uniquely positioned to redefine how hospitals deliver safe, efficient and high-quality care."
Hybrid cancer care company Daymark Health has secured $20 million in Series A funding.
The round was led by Healthier Capital, with participation from Blue Venture Fund, as well as existing investors Maverick Ventures, Yosemite and Oncology Ventures.
The company offers virtual and in-home care to help cancer patients with clinical, social and mental health needs in collaboration with oncologists and primary care providers. Daymark partners directly with health plans.
Daymark Health will use the funds to scale its cancer care platform and establish new partnerships with plans and providers nationwide.
AmplifyMD, a virtual care company serving hospitals and health systems, announced that it has secured $20 million in Series B funding.
Forerunner Ventures led the raise, with participation from strategic partner Memorial Hermann Health System, F-Prime, Greylock and Tau Ventures.
The California-based company, which launched in 2019, will use the funds to scale its platform, including the development of AI and clinical workflow capabilities. It also aims to form more strategic partnerships.
"At Memorial Hermann, we look for innovation that addresses challenges in a fundamentally different way," Feby Abraham, executive vice president and chief strategy officer at Memorial Hermann, said in a statement.
"AmplifyMD stands out because it combines AI-enabled workflows with on-demand specialty coverage, creating a scalable model that expands access, improves quality and lowers costs."
